SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SLDB

Solid Biosciences Inc. (NASDAQ:SLDB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$6.25-$0.19 (-2.95%)
 
Market cap
$698M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 26, 2018
Market Cap$697.57M+27.3%
Revenue (ttm)$0
Net Income-$215.27M-28.8%
EPS-$1.79+21.8%
Shares Out111.61M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,558,939
Open$6.22
Previous Close$6.44
Day's Range$6.19 - $6.53
52-Week Range$4.65 - $11.45
Beta2.63
AnalystsBuy
Price Target$22.25(+256.00%)
Earnings DateMar 18, 2027

About SLDB

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

Address
500 Rutherford Avenue, Charlestown, MA, 02129, US
Market Cap
698 million
Employees
121
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.59M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $18.00 (+188.0%)

2 firms rating SLDB in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From SLDB’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-2.95%
5 Days
-7.54%
1 Month
+0.97%
6 Months
-5.59%
1 Year
+27.29%

$SLDB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SLDB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SLDB's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SLDB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New SLDB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SLDB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in SLDB

VTIVanguard Morningstar Total Stock Market ETF$15.15M
IWMiShares Russell 2000 ETF$12.71M
XBIState Street SPDR S&P Biotech ETF$11.55M
VXFVanguard Extended Market ETF$4.59M
IBBiShares Biotechnology ETF$4.30M
DFASDimensional - US Small Cap ETF$3.95M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from SLDB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
17
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF0.91%
BBCVirtus Biotech Clinical Trials ETF0.79%
MNTLTema Neuroscience And Mental Health ETF0.57%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.50%
SBIOALPS Medical Breakthroughs ETF0.49%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.38%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.31%
IWCiShares Micro-Cap ETF0.14%
OPTZOptimize Strategy Index ETF0.13%
XBIState Street SPDR S&P Biotech ETF0.12%
FSEGFidelity Enhanced Small Cap Growth ETF0.07%
VMO.TOVanguard Global Momentum Factor ETF0.06%

Weight is the stock’s share of each fund’s holdings.